The role of preoperative preparation in giant cervical uterine myomatosis: case Report
DOI:
https://doi.org/10.47464/MetroCiencia/vol31/1/2023/72-80Keywords:
Myoma, Leuprolide, Hysterectomy, Uterine Artery Embolization, Magnetic Resonance, Surgical Procedure, ProgestinsAbstract
Uterine myomatosis is the most common tumor in women. It has been estimated that 70 to 80% of women will present some form of uterine myoma during their life. The size and location of uterine myomas may differ according to each patient, however, the cervical myoma represents only 5% of all its types and locations. Its clinical presentation varies from a myoma located in the uterus itself, and it is extremely rare for this type of myoma to exceed 10 cm. The diagnostic study of uterine myomatosis consists of ultrasonography and the need for complementary imaging tests will depend on the quality of the ultrasound. Magnetic resonance imaging is the best study to perform in the case of an unsatisfactory ultrasonography. It provides more specific information compared to ultrasonography and provides key information for an adequate pre-surgical preparation. The appropriate therapeutic strategy is determined by the clinic, location, size, and number of fibroids. Myomatosis is the most frequent indication for hysterectomy, however, there are non-curative alternatives such as myomectomy, medical treatment with GnRh analogues and even interventional radiology that have shown good results in the prognosis and quality of life of these patients.
Downloads
References
Stewart EA. Uterine Fibroids. N Engl J Med [Internet]. 2015;372(17):1646–55. Available from: http://dx.doi.org/10.1056/nejmcp1411029
Bulun SE. Uterine fibroids. N Engl J Med [Internet]. 2013;369(14):1344–55. Available from: http://dx.doi.org/10.1056/NEJMra1209993
Quiala LNM, Valdés MÁS, Hernández YA. Leiomioma uterino gigante. Reporte de un caso. Finlay [Internet]. 2014 [cited 2022 jan];4(3):210–5. Available from: http://revfinlay.sld.cu/index.php/finlay/article/view/304
Expert Panel on Interventional Radiology:; Knuttinen MG, Stark G, Hohenwalter EJ, Bradley LD, Braun AR, Gipson MG, Kim CY, Pinchot JW, Scheidt MJ, Sella DM, Weiss CR, Lorenz JM. ACR Appropriateness Criteria® Radiologic Management of Uterine Leiomyomas. J Am Coll Radiol. 2018 May;15(5S):S160-S170. doi: 10.1016/j.jacr.2018.03.010. PMID: 29724419.
Kalyan S, Sharma S. Giant uterine leiomyoma: a case report with literature review. Int J Reprod Contracept Obstet Gynecol [Internet]. 2018;7(11):4779. Available from: http://dx.doi.org/10.18203/2320-1770.ijrcog20184548
Faerstein E, Szklo M, Rosenshein NB. Risk factors for uterine leiomyoma: a practice-based case-control study. II. Atherogenic risk factors and potential sources of uterine irritation. Am J Epidemiol [Internet]. 2001;153(1):11–9. Available from: http://dx.doi.org/10.1093/aje/153.1.11
Guzman GS, Manalo EM. Myomatous erythrocytosis syndrome: A case series. Case Rep Womens Health [Internet]. 2019;24(e00139):e00139. Available from: http://dx.doi.org/10.1016/j.crwh.2019.e00139
Naz S, Rehman A, Riyaz A, Jehangir F, Naeem S, Iqbal T. Leiomyoma: Its variants and secondary changes A five-year study. J Ayub Med Coll Abbottabad. 2019;31(2):192–5.
García C, Parra F, Sancho M. Acetato de ulipristal 5 mg (Esmya®) como primera opción en el manejo terapéutico de los miomas uterinos sintomáticos. Prog Obstet Ginecol. 2016;59(5):277–82.
Lim PT, Tan CH, Chia HL, Phoon J. Management of a giant uterine leiomyoma. BMJ Case Rep [Internet]. 2018;2018:bcr-2017-224052. Available from: http://dx.doi.org/10.1136/bcr-2017-224052
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Daniel Fernando Narváez Cervantes, Luis Fernando Suárez Lopez, María Esther Abdo Rojas, Nicole Berenice Narváez Cervantes
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
